SCM
XLO icon

Stonepine Capital Management’s Xilio Therapeutics XLO Stock Holding History

Stonepine Capital Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17M Buy
225,994
+161,832
+252% +$1.35M 1.22% 25
2026
Q1 		$540K Buy
64,162
+55,143
+611% +$452K 0.22% 56
2025
Q4 		$80.8K Buy
+9,019
New +$94.7K 0.06% 64

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stonepine Capital Management's XLO Position: Q2 2026 in Review

Stonepine Capital Management increased its Xilio Therapeutics (XLO) stake by 252% in Q2 2026, buying an estimated $1.35M and bringing the position to 225,994 shares worth $2.17M. The position accounts for 1.22% of the portfolio, ranked #25.

Stonepine Capital Management first reported a position in XLO in Q4 2025 and has held it in 3 quarters since. 26 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Stonepine Capital Management held 225,994 shares of Xilio Therapeutics worth $2.17M as of Q2 2026.
  • Stonepine Capital Management bought 161,832 Xilio Therapeutics shares in Q2 2026, an estimated $1.35M.
  • Xilio Therapeutics made up 1.22% of Stonepine Capital Management's portfolio in Q2 2026, its #25 holding.
  • Stonepine Capital Management first reported a position in Xilio Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 26 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.